| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Lβ2 Activation by Chemokine1 Division of Hematology, School of Cancer Studies and 2 Center for Cell Imaging, School of Biological Sciences, University of Liverpool, Liverpool, United Kingdom
Requests for reprints: Kathleen J. Till, University of Liverpool, Daulby Street, Liverpool, L12 4XZ, United Kingdom. Phone: 44-151-706-4282; Fax: 44-151-706-4311; E-mail: k.j.till{at}liv.ac.uk.
Key Words: CLL Integrins Chemokines Rap1 Motility
Chemokine-induced activation of
4β1 and
Lβ2 integrins (by conformational change and clustering) is required for lymphocyte transendothelial migration (TEM) and entry into lymph nodes. We have previously reported that chemokine-induced TEM is defective in chronic lymphocytic leukemia (CLL) and that this defect is a result of failure of the chemokine to induce polar clustering of
Lβ2; engagement of
4β1 and autocrine vascular endothelial growth factor (VEGF) restore clustering and TEM. The aim of the present study was to characterize the nature of this defect in
Lβ2 activation and determine how it is corrected. We show here that the
Lβ2 of CLL cells is already in variably activated conformations, which are not further altered by chemokine treatment. Importantly, such treatment usually does not cause an increase in the GTP-loading of Rap1, a GTPase central to chemokine-induced activation of integrins. Furthermore, we show that this defect in Rap1 GTP-loading is at the level of the GTPase and is corrected in CLL cells cultured in the absence of exogenous stimuli, suggesting that the defect is the result of in vivo stimulation. Finally, we show that, because Rap1-induced activation of both
4β1 and
Lβ2 is defective, autocrine VEGF and chemokine are necessary to activate
4β1 for ligand binding. Subsequently, this binding and both VEGF and chemokine stimulation are all needed for
Lβ2 activation for motility and TEM. The present study not only clarifies the nature of the
Lβ2 defect of CLL cells but is the first to implicate activation of Rap1 in the pathophysiology of CLL. [Cancer Res 2008;68(20):8429–36]
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |